20 After 52 weeks, steatohepatitis resolved without fibrosis progression in 44%, 56%, and 62% of participants receiving tirzepatide at doses of 5 mg, 10 mg, and 15 mg, respectively, compared to 10% in the placebo group
Medical programs can address stubborn midlife weight and hormone issues that typical diets overlook
The STEP trials further highlight its exceptional effectiveness in weight control, with participants achieving up to 20% weight loss alongside improvements in obesity-related comorbidities
However, the weight loss it supports could help in several ways: Reducing the mechanical load on weight-bearing joints Lowering systemic inflammation that contributes to cartilage damage Improving mobility, which makes it easier to exercise and strengthen the muscles around joints An ongoing registered trial called STOP Knee OA is investigating the effect of tirzepatide in people with obesity and knee osteoarthritis
Kosiborod reports having served as a consultant or as an advisory board member for 35Pharma, Alnylam, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Dexcom, Eli Lilly, Esperion Therapeutics, Janssen, Lexicon Pharmaceuticals, Merck (Diabetes and Cardiovascular), Novo Nordisk, Pfizer, Pharmacosmos, scPharmaceuticals, Structure Therapeutics, Vifor Pharma, and Youngene Therapeutics